Printer Friendly

DEPRENYL RESEARCH LIMITED REPORTS EARNINGS

 DEPRENYL RESEARCH LIMITED REPORTS EARNINGS
 TORONTO, Feb. 5 /PRNewswire/ -- Deprenyl Research Limited


(NASDAQ: DEPLF - TSE: DEP)) usually issues its results quarterly but the company is making as exception because last Thursday a Toronto brokerage firm, Burns Fry Limited, put out a report saying that for 1992 earnings of Deprenyl Research Limited would be 30 cents per share. This resulted in some very heavy selling of the company's stock.
 In the month of January, Eldepryl(R) sales were $687,000 vs. $299,000 last January. January sales are historically the lowest month of the year because wholesalers stock up at the end of the year prior to an anticipated annual price increase. Export sales of Alzene(TM) began eight weeks ago and continue to rise steadily.
 Earnings for the month of January 1992 were 19 cents per share and early indications are that Deprenyl Research Limited will have another record year. Although January earnings will not be repeated each month, total 1992 earnings will clearly exceed the Burns Fry Limited estimate.
 Deprenyl Research Limited is an independent Canadian pharmaceutical company which markets drugs to treat central nervous system disorders. It principal product is Eldepryl which is used to treat Parkinson's disease.
 -0- 2/5/92
 /CONTACT: Mortin P. Schulman, M.D., co-chairman, or James P. Doherty, president, 416-537-4372, both of Deprenyl Research; or Irving L. Strauss, chairman of Strauss Communications, 212-768-2477, for Deprenyl Research/
 (DEPLF) CO: Deprenyl Research Limited ST: Ontario IN: MTC SU: ERN PS-SM -- NY001 -- 7009 02/05/92 08:30 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 5, 1992
Words:253
Previous Article:BLOCKBUSTER ACQUIRES MAJORITY OF CITYVISION COMMON SHARES
Next Article:CAMBRIDGE BIOTECH RESTRUCTURES DIAGNOSTICS BUSINESS INTO TWO DIVISIONS; APPOINTS EXECUTIVE VP/GM AMERICAS/FAR EAST UNIT
Topics:


Related Articles
DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
DEPRENYL USA REPORTS RESULTS FOR SECOND QUARTER AND SIX MONTHS ENDING JUNE 30, 1992
DEPRENYL USA, INC. REPORTS RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPT. 30, 1992; EXPECTS TO FILE ITS FIRST INVESTIGATIONAL NEW DRUG
DEPRENYL RESEARCH LIMITED ANNOUNCES FOURTH QUARTER RESULTS TO BE RELEASED MID-FEBRUARY
DEPRENYL USA REPORTS YEAR END 1992 RESULTS; CONFIRMS ALA PHOTODYNAMIC DEVELOPMENT ON SCHEDULE; PROPOSES NAME CHANGE TO DUSA PHARMACEUTICALS
DEPRENYL RESEARCH REPORTS EARNINGS
DEPRENYL USA REPORTS FIRST QUARTER RESULTS ON PLAN INITIAL CLINICAL TRIALS PROCEEDING ON SCHEDULE
MEDICIS REPORTS RETIREMENT OF TWO DEBT OBLIGATIONS
DRAXIS HEALTH INC. REPORTS EARNINGS FOR SECOND QUARTER, FIRST HALF
DRAXIS Announces Results for the Third Quarter Ended September 30, 1996

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters